Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

Last updated: October 3, 2012
Sponsor: LG Life Sciences
Overall Status: Completed

Phase

4

Condition

Hormone Deficiencies

Severe Short Stature

Growth Hormone Deficiencies/abnormalities

Treatment

N/A

Clinical Study ID

NCT01605331
LG-SHCL007
  • Ages > 20
  • All Genders

Study Summary

As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life. Patients, however, do have to tolerate daily injections of GH (rhGH).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women aged ≥ 20 years with diagnosed GH deficiency (caused by pituitary tumor, trauma, other pituitary disease)

Study Design

Total Participants: 132
Study Start date:
December 01, 2009
Estimated Completion Date:
September 30, 2010